Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 3/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155096 | 0.90 | KDM4E (0.52) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL13315605 | 0.90 | KCNH2 (0.42) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL3129389 | 0.89 | KDM4E (0.51) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL2601633 | 0.87 | KCNH2 (0.44) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL5792882 | 0.87 | GSK3B (0.55) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL541516 | 0.86 | KCNH2 (0.53) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL2108872 | 0.85 | KDM4E (0.56) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL10014153 | 0.85 | KCNH2 (0.55) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL13744461 | 0.85 | KDM4E (0.47) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 | |
| SCHEMBL12917137 | 0.85 | KDM4E (0.47) | KDM4EHPGDKCNH2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928892-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF MOXIFLOXACIN HYDROCHLORIDE | MANKIND PHARMA LTD (IN) | 2018-03-21 | — | — | EP | disclosed |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-9133213-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2015-09-15 | — | — | US | disclosed |
| CN-102558145-B | Method for preparing balofloxacin | UNIV CHINA PHARMA | 2014-04-16 | — | — | CN | disclosed |
| EP-1709044-B2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8513231-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fü Kombinatorische Chemie (DE) | 2013-08-20 | — | — | US | disclosed |
| US-8501774-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8268812-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fül Kombinatorische Chemie (DE) | 2012-09-18 | — | — | US | disclosed |
| US-7179805-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-7179805-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| EP-1709044-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1620098-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005058888-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004096221-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-11-11 | — | — | WO | disclosed |
| US-6656952-B2 | As antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| EP-0995744-B1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020072608-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0995744-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072608-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVE | Q6ZSR9, MRPL21, ABCC1 | KDM4E 707/4885HPGD 1909/4885KCNH2 130/4885 |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | KDM4E 4447/4885HPGD 278/4885KCNH2 2774/4885 |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | KDM4E 4287/4885HPGD 213/4885KCNH2 1454/4885 |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | KDM4E 4447/4885HPGD 278/4885KCNH2 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.